Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Health agency reveals scourge of fake drugs in developing world

WHO data suggest around 10% of medications in poorer countries are fraudulent or substandard.

Fake medicines are removed from a shop during a police raid of a market in Côte d'Ivoire. Credit: Issouf Sanogo/AFP/Getty

One in ten medicines in developing countries is fake or substandard, data from the World Health Organization (WHO) suggest.

Malaria drugs and antibiotics are among the most commonly reported, the agency found. But the problem extends to a variety of medications, including those for cancer, heart disease and HIV, as well as contraceptives and painkillers (see 'Fake drugs').

The latest figures come from a pair of reports1,2 released by the WHO on 28 November — the agency’s first on fake medicines in about a decade. The findings focus on fraudulent and poor-quality medications in low- and middle-income countries: of 1,500 cases reported to the agency in the past four years, 42% were from Africa, 21% from the Americas and 21% from Europe.

Data on the issue had until now been scant, because there was no mechanism to track the problem. The WHO set up a global system to report inferior medicines in 2013, tracking drugs that are deliberately fraudulent, fail to meet quality standards, or which have not been evaluated or authorized for market. These medications are often referred as counterfeit drugs, but the agency stopped using the term in May to shift the focus from intellectual-property issues to public health.

The cases captured so far are probably just the tip of the iceberg, the WHO says, because many more go unreported. So far, the agency has trained 550 people in 141 countries to track these drugs. “The more one looks, the more one finds,” it says.

Public-health problem

The studies estimate that roughly 10% of medicines in circulation in poorer countries — where technical capacity to enforce quality standards is often limited — are substandard or falsified. Cases aren’t limited to expensive or well-known medications, and are split about equally between generic and patented drugs. One analysis in the reports estimates that up to 169,000 children could be dying each year from pneumonia because of inferior antibiotics.

Poor-quality medicines not only fail to treat or prevent disease, they also risk worsening antimicrobial resistance, says Mariângela Simão, the WHO’s assistant director-general for Access to Medicines, Vaccines and Pharmaceuticals. People taking substandard antibiotics that don't fully treat an infection could develop resistant infections that spread.

The findings underestimate the scourge of fake drugs, says Marc Gentilini, a member of the French Academy of Medicine who studies the issue. But crucially, he adds, there is not yet a plan in sight to tackle the problem.

References

  1. WHO. WHO Global Surveillance and Monitoring System for substandard and falsified medical products (2017); available at http://bit.ly/2zpxoeu

  2. WHO. A study on the public health and socioeconomic impact of substandard and falsified medical products (2017); available at http://bit.ly/2Ak1mjv

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Casassus, B. Health agency reveals scourge of fake drugs in developing world. Nature (2017). https://doi.org/10.1038/nature.2017.23051

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/nature.2017.23051

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing